This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2018 Mar 26;60(1543):53-55.

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy

No authors listed

PMID: 29635265

Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy

No authors listed. Med Lett Drugs Ther. 2018.

. 2018 Mar 26;60(1543):53-55.

PMID: 29635265

No abstract available

Keywords: adverse effects; dosage; drug interactions; efficacy; eye; safety.

PubMed Disclaimer

Similar articles

Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.
Weng CY. Weng CY. Ophthalmol Retina. 2019 May;3(5):450. doi: 10.1016/j.oret.2019.02.007. Ophthalmol Retina. 2019. PMID: 31044739 No abstract available.
Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C, Scott LJ. Kang C, et al. Mol Diagn Ther. 2020 Aug;24(4):487-495. doi: 10.1007/s40291-020-00475-6. Mol Diagn Ther. 2020. PMID: 32535767 Review.
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, Marshall KA, McCague S, Reichert H, Davis M, Simonelli F, Leroy BP, Wright JF, High KA, Bennett J. Maguire AM, et al. Ophthalmology. 2019 Sep;126(9):1273-1285. doi: 10.1016/j.ophtha.2019.06.017. Epub 2019 Jun 22. Ophthalmology. 2019. PMID: 31443789 Clinical Trial.
Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.
Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Maguire AM, et al. Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029. Epub 2020 Dec 3. Mol Ther. 2021. PMID: 33278565 Free PMC article. Review.
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. Russell S, et al. Lancet. 2017 Aug 26;390(10097):849-860. doi: 10.1016/S0140-6736(17)31868-8. Epub 2017 Jul 14. Lancet. 2017. PMID: 28712537 Free PMC article. Clinical Trial.

See all similar articles

Cited by

GPR108 Is a Highly Conserved AAV Entry Factor.
Dudek AM, Zabaleta N, Zinn E, Pillay S, Zengel J, Porter C, Franceschini JS, Estelien R, Carette JE, Zhou GL, Vandenberghe LH. Dudek AM, et al. Mol Ther. 2020 Feb 5;28(2):367-381. doi: 10.1016/j.ymthe.2019.11.005. Epub 2019 Nov 13. Mol Ther. 2020. PMID: 31784416 Free PMC article.
Generation of a 3D Liver Model Comprising Human Extracellular Matrix in an Alginate/Gelatin-Based Bioink by Extrusion Bioprinting for Infection and Transduction Studies.
Hiller T, Berg J, Elomaa L, Röhrs V, Ullah I, Schaar K, Dietrich AC, Al-Zeer MA, Kurtz A, Hocke AC, Hippenstiel S, Fechner H, Weinhart M, Kurreck J. Hiller T, et al. Int J Mol Sci. 2018 Oct 12;19(10):3129. doi: 10.3390/ijms19103129. Int J Mol Sci. 2018. PMID: 30321994 Free PMC article.
Viral vectors as a novel tool for clinical and neuropsychiatric research applications.
Wang Y, Hu Z, Ju P, Yin S, Wang F, Pan O, Chen J. Wang Y, et al. Gen Psychiatr. 2018 Oct 25;31(2):e000015. doi: 10.1136/gpsych-2018-000015. eCollection 2018. Gen Psychiatr. 2018. PMID: 30582128 Free PMC article.
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency.
Mével M, Pichard V, Bouzelha M, Alvarez-Dorta D, Lalys PA, Provost N, Allais M, Mendes A, Landagaray E, Ducloyer JB, Toublanc E, Galy A, Brument N, Lefevre GM, Gouin SG, Isiegas C, Le Meur G, Cronin T, Le Guiner C, Weber M, Moullier P, Ayuso E, Deniaud D, Adjali O. Mével M, et al. Mol Ther Methods Clin Dev. 2024 Jan 17;32(1):101187. doi: 10.1016/j.omtm.2024.101187. eCollection 2024 Mar 14. Mol Ther Methods Clin Dev. 2024. PMID: 38327809 Free PMC article.
Current Approaches to Low Vision (Re)Habilitation.
Altınbay D, İdil ŞA. Altınbay D, et al. Turk J Ophthalmol. 2019 Jun 27;49(3):154-163. doi: 10.4274/tjo.galenos.2018.53325. Turk J Ophthalmol. 2019. PMID: 31245978 Free PMC article. Review.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Medical Letter on Drugs and Therapeutics
Medical
- MedlinePlus Health Information